Coronary CT has become one of the most powerful imaging technologies for cardiovascular risk assessment. However, an important clinical question remains: Should Coronary CT Angiography (CCTA) be used routinely to screen asymptomatic individuals, or does Coronary Artery Calcium (CAC) scanning already provide sufficient information for preventive care? This presentation reviews the current evidence comparing CAC scoring and CCTA in primary prevention, examining their predictive

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial Vision 2030 presents HeartLung.AI’s long-term vision for transforming medical imaging into a comprehensive, AI-powered preventive healthcare ecosystem. Rather than generating a diagnostic report alone, the platform is designed to convert a single medical image into a personalized prevention strategy that follows patients throughout their lives. The proposed Preventive Imaging Agentic AI framework integrates multiple in

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual Care The LDCT Mega Trial is an ambitious vision for one of the largest prospective clinical studies ever proposed in artificial intelligence, designed to evaluate whether an Agentic AI-powered preventive imaging ecosystem can improve long-term health outcomes compared with conventional medical care. The proposed randomized trial plans to enroll 100,000 participants across 250 cl

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group AI-CVD is an advanced artificial intelligence platform that transforms routine coronary artery calcium (CAC) and chest CT scans into comprehensive cardiovascular risk assessments by extracting a wide range of imaging biomarkers from a single examination. Rather than relying solely on traditional clinical risk factors, AI-CVD analyzes multiple cardiome

AI-CAC introduces a novel artificial intelligence approach for coronary plaque analysis using non-contrast cardiac CT (CAC) scans, offering the potential to extract plaque characteristics traditionally obtainable only from contrast-enhanced coronary CT angiography (CCTA). Conventional CCTA provides excellent visualization of coronary anatomy but requires intravenous contrast administration and is affected by scanner-, software-, and observer-related variability. AI-CAC addres

Agatston-2.0 is a next-generation artificial intelligence framework developed to enhance cardiovascular risk assessment in individuals with Agatston coronary artery calcium (CAC) scores below 100—a population that represents nearly 75% of individuals undergoing CAC scanning and accounts for a substantial proportion of future coronary heart disease events. Rather than relying solely on conventional calcium scoring, Agatston-2.0 introduces advanced AI-derived biomarkers that an

AutoLung AI is an advanced artificial intelligence platform designed to improve lung cancer detection and long-term risk prediction using a wide range of CT imaging studies—not only dedicated low-dose lung cancer screening CT, but also routine chest CT, coronary artery calcium (CAC) scans, and coronary CT angiography (CCTA). Unlike conventional approaches that primarily focus on pulmonary nodules, AutoLung AI integrates whole-lung imaging biomarkers with nodule-level analysis